Otros idiomas Coherus BioSciences, Inc.

Acciones

CHRS

US19249H1032

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 25/06/2024			Varia. Cinco días.	Varia. 1 de enero.
1,58 ^USD	-3,07 %		-2,47 %	-52,55 %

07/06	El férreo control de AbbVie sobre el mercado de Humira hace temer por los biosimilares	RE
05/06	Coherus BioSciences, Inc. nombra a Rita Karachun miembro de su Consejo de Administración	CI

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors	05/06
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors	05/06
Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors	05/06
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference	30/05
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	23/05
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 Antibody, CHS-114, at the 2024 American Society of Clinical Oncology Annual Meeting	23/05
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA	23/05
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA	23/05
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	10/05
Novavax, Insulet, Moderna... Les valeurs à suivre aujourd'hui à Wall Street	10/05
Coherus BioSciences : réduit sa perte au 1er trimestre, mais déçoit les investisseurs	10/05
Earnings Flash (CHRS) COHERUS BIOSCIENCES Posts Q1 Revenue $77.1M, vs. Street Est of $83.8M	09/05
Coherus BioSciences: Q1 Earnings Snapshot	09/05
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI with ENB Therapeutics ENB-003 for the Treatment of Ovarian Cancer	09/05
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan	09/05
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan	09/05
Coherus Biosciences, Inc. Enters into a Senior Secured Term Loan Facility	09/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Coherus BioSciences, Inc.

Acciones

CHRS

US19249H1032

Otros idiomas

Filtros